Status: Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD5 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.

Participants needed: 36

Trial details

Phase: Phase 1, Phase 2Age: 14-70Biological sex: AllType: InterventionalSponsor: Beijing GoBroad HospitalUpdated: Jun 15, 2025Locations: 3

Eligibility criteria

Relapsed or refractory CD7-positive T-cell lymphomas that were treated with with... [+4]

Patients with history of allogeneic HSCT but PBMNC is not available from prior-... [+13]

Status: Recruiting

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.